Firm Has Outperformed Friends and Related Indices Since Unveiling its December 2020 Worth Enhancement Plan

70% of Board’s Unbiased Administrators Have Been Appointed Over the Final 4 Years, Together with 4 Administrators Designated or Supported by Shareholders

Firm Launches www.AlkermesValue.com, Offering Extra Info for Shareholders

Alkermes’ Board Recommends Shareholders Vote “FOR” Alkermes’ Director Nominees on Firm’s WHITE Proxy Card

DUBLIN, Might 25, 2023 /PRNewswire/ — Alkermes plc (Nasdaq: ALKS) (the Firm) right this moment filed its definitive proxy assertion with the U.S. Securities and Change Fee (SEC) and issued a letter to its shareholders in reference to the Firm’s upcoming 2023 Annual Normal Assembly of Shareholders (the Annual Assembly), which is scheduled to be held on June 29, 2023. The letter particulars the Firm’s profitable execution and worth creation because the announcement of its Worth Enhancement Plan in December 2020. The Worth Enhancement Plan is comprised of quite a few initiatives, together with Board refreshment, analysis of strategic alternatives and institution of long-term profitability targets. Key highlights from the letter embrace that Alkermes:

• Generated a share worth improve of 49% because the Firm introduced its Worth Enhancement Plan on December 10, 2020. Since then, the Firm’s whole shareholder return (TSR) has outperformed its peers1 by 61%, the XBI biotech index by 83% and the NBI biotech index by 56%.2 Alkermes’ TSR has additionally outperformed its friends and the XBI and NBI on a 1-year and 3-year trailing foundation and different related timeframes.
• Appointed seven new impartial administrators to the Firm’s board of administrators (the Board) over the past 4 years, whereas 5 longer-serving administrators have retired. The newly appointed administrators, which comprise 70% of the Board’s impartial administrators, embrace a director designated by activist hedge fund Sarissa Capital Administration LP (Sarissa) in November 2021 (Cato T. Laurencin, M.D., Ph.D.), a director designated by Elliott Advisors (UK) (Elliott) in Might 2021 (Emily Peterson Alva), and two administrators appointed with the help of Elliott in December 2020 (David A. Daglio and Brian P. McKeon).
• Enhanced the Firm’s company governance based mostly on shareholder suggestions, the evolving wants of the enterprise and developments in governance greatest practices. These actions included, amongst others: declassifying the Board and establishing a plurality voting commonplace for contested director elections; forming the Monetary Working Committee of the Board to supervise achievement of the Firm’s profitability targets; refreshing the Board’s Lead Unbiased Director and the membership and management of the Nominating and Company Governance Committee of the Board; enhancing the Firm’s govt compensation packages; and limiting the variety of public firm boards on which administrators might serve.
• Expanded its business portfolio by securing regulatory approvals of two new Alkermes-developed merchandise (LYBALVI® and VUMERITY®) and grew web gross sales of its proprietary merchandise, and superior and expanded its pipeline beneath a disciplined and built-in growth strategy.
• Initiated the separation of the Firm’s oncology enterprise from its neuroscience enterprise and, in reference to this transaction, submitted a confidential draft Type 10 in April 2023.
• Drove sturdy efficiency and enterprise momentum by a give attention to operational effectivity, disciplined capital allocation, and profitability, together with by calibrating Alkermes’ price construction to appropriately help the Firm’s strategic priorities and progress alternatives.

Regardless of the Firm’s constructive momentum and robust efficiency over this timeframe, Sarissa notified Alkermes in February 2023 of its intent to appoint three director candidates for election on the Annual Assembly.

The Board recommends that shareholders vote “FOR” all seven of the Board’s director nominees – Emily Peterson Alva, Cato T. Laurencin, M.D., Ph.D., Brian P. McKeon, Christopher I. Wright, M.D., Ph.D., Shane M. Cooke, Richard B. Gaynor, M.D. and Richard F. Pops – utilizing the Firm’s WHITE proxy card. The Firm’s proxy assertion and different vital info and assets associated to the Annual Assembly might be discovered at www.AlkermesValue.com or investor.alkermes.com/investor-relations.

The total textual content of the letter being despatched to shareholders follows:

Pricey Alkermes Shareholder,

Your vote on the Alkermes plc (the “Firm” or “Alkermes”) Annual Normal Assembly of Shareholders (the “Annual Assembly”) on June 29, 2023 is essential.

Alkermes is a totally built-in, international biopharmaceutical firm centered on growing modern new medicines to deal with unmet affected person wants and on driving long-term, sustainable worth for its shareholders. In 2019, pushed by the Firm’s share efficiency, operational issues, and shareholder suggestions, the Firm’s board of administrators (the “Board”) and administration acknowledged the necessity to realign the Firm’s priorities, refine its strategic and operational focus, and impact sure governance adjustments. The Board initiated vital Board refreshment efforts and, in December 2020, introduced its Worth Enhancement Plan, which is comprised of quite a few initiatives, together with continued Board refreshment, analysis of strategic alternatives and institution of long-term profitability targets.

Alkermes’ sturdy efficiency because the announcement of the December 2020 Worth Enhancement Plan is a direct results of the Firm’s execution towards its three strategic priorities, as overseen by its just lately refreshed Board:

For every of those strategic priorities, Alkermes has established clear targets designed to drive shareholder worth, together with, for 2023: 

• Drive the launch and continued uptake of LYBALVI® by execution of the Firm’s business technique.
• Advance ALKS 2680, the Firm’s orexin 2 receptor agonist, together with by establishing its preliminary security and tolerability profile and producing medical proof-of-concept knowledge.
• Separate the Firm’s oncology enterprise from its neuroscience enterprise, which the Board believes will unlock shareholder worth by enhancing the efficiency of each companies and accelerating profitability for the neuroscience enterprise.

Underpinning these priorities and targets and the operation of the enterprise is the Firm’s basis of sturdy company governance, dedication to sufferers and staff, and its dedication to working in an moral and accountable method.

ALKERMES HAS HAD STRONG RECENT PERFORMANCE AND MOMENTUM

The Firm has been centered on evolving its enterprise and establishing a robust basis to drive shareholder worth. These efforts started previous to activist hedge fund Sarissa Capital Administration LP (“Sarissa”) turning into a shareholder of Alkermes. Because the Firm introduced its Worth Enhancement Plan in December 2020, Alkermes’ share worth has elevated by 49%, and the Firm has outperformed its peers1 by 61%, the XBI biotech index by 83% and the NBI biotech index by 56%.2 Alkermes’ whole shareholder return (“TSR”) has additionally outperformed its friends and the XBI and NBI over varied different timeframes, together with on a 1-year and 3-year trailing foundation.

Because the announcement of the December 2020 Worth Enhancement Plan, the Firm’s enterprise worth to a subsequent twelve-month income a number of has elevated by roughly 51% from 2.5x to three.8x, reflecting traders’ recognition of the Firm’s efficiency and future prospects.

Regardless of the Firm’s constructive momentum and robust execution of its enterprise technique over this timeframe, Sarissa notified Alkermes in February 2023 of its intent to appoint three director candidates for election on the Annual Assembly. That is the third yr in a row Sarissa has submitted nominations to the Firm, following a settlement in 2021 that resulted within the appointment to the Board of a Sarissa-designated director (who continues to serve on the Board) and Sarissa’s abandonment of its earlier proxy marketing campaign in 2022.

Earlier this yr, the Board performed its annual analysis of the specified mixture of abilities, experiences and variety of views to help the Firm’s strategic priorities, and the 4 impartial administrators on the Board’s Nominating and Company Governance Committee interviewed and punctiliously thought of all of Sarissa’s candidates. Following the committee’s analysis, the Board decided that the important thing attributes and expertise of the three Sarissa nominees had been neither additive to the Board right now nor per the skillset beforehand recognized by the Board as vital in a brand new director. The Board due to this fact decided that appointing Sarissa’s nominees as administrators wouldn’t be in the most effective pursuits of the Firm and its shareholders. However the foregoing choice, the Alkermes Board has made quite a few makes an attempt to achieve a decision with Sarissa and quite a few the Firm’s impartial administrators have continued to debate with Sarissa methods to forestall a proxy contest.

ALKERMES HAS A REFRESHED, HIGHLY ENGAGED, DIVERSE AND INDEPENDENT BOARD WITH STRONG GOVERNANCE

Alkermes has energetic, expert and extremely skilled Board members who’re deeply engaged in oversight of the Firm and its technique. Beginning in 2019, the Board initiated vital Board refreshment efforts and carried out new initiatives to reinforce its company governance, its compensation packages and its enterprise. Since that point, Alkermes has appointed seven new impartial administrators to the Board and 5 longer-serving administrators have retired. Not one of the new, impartial administrators appointed had any earlier connections to the Firm or its management group. These new administrators, who comprise 70% of the Board’s impartial administrators, embrace a director designated by Sarissa in November 2021 (Cato T. Laurencin, M.D., Ph.D.), a director designated by Elliott in Might 2021 (Emily Peterson Alva), and two administrators appointed with the help of Elliott in December 2020 (David A. Daglio and Brian P. McKeon). In 2022, in reference to its Board refreshment efforts, Alkermes appointed Nancy J. Wysenski as its new Lead Unbiased Director.

The Board refreshment efforts added numerous backgrounds, abilities, experiences, and views to the Board which can be related to the Firm’s trade and operations and aligned with its enterprise technique. The Board is comprised of people with in depth expertise in quite a lot of areas which can be crucial to the Firm’s enterprise technique, together with life sciences trade expertise; business advertising and gross sales expertise; finance and accounting expertise; administration and governance expertise; buyside investor perspective and expertise; and company technique and sophisticated transactional expertise.

Alkermes maintains sturdy company governance and Board oversight practices that promote the long-term pursuits of its shareholders. The Firm and the Board recurrently interact with shareholders in respect of governance and different issues and the Board frequently critiques and, because it deems applicable, refines its governance insurance policies and practices. On account of shareholder suggestions, the evolving wants of the enterprise and developments in governance greatest practices, the Board has, lately, taken the next actions, amongst others, to reinforce Alkermes’ company governance, together with:

• Declassified the Board: In July 2020, the Firm introduced its plans to declassify the Board and, on the Firm’s 2021 annual assembly, the Firm’s shareholders accepted the declassification of the Board over a three-year interval. This course of can be accomplished subsequent yr.

• Adopted Plurality Voting for Contested Elections: In Might 2022, the Board convened an Extraordinary Normal Assembly of Shareholders at which, on the Board’s advice, the Firm’s shareholders accepted the institution of a plurality voting commonplace for contested director elections.

• Shaped the Monetary Working Committee of the Board: In December 2020, the Board shaped the Monetary Working Committee of the Board, on which all three Elliott-supported administrators serve, to supervise achievement of the Firm’s profitability targets and consider a broad vary of potential strategic choices associated to the Firm’s non-core belongings, together with potential monetization and divestiture alternatives.

• Refreshed the Nominating and Company Governance Committee: Throughout 2022, the Board added three new impartial committee members and appointed a brand new committee chair. All 4 members of the committee are numerous when it comes to gender and/or race/ethnicity. Two members of the committee, together with Sarissa’s director designee, had been appointed to the Board in collaboration with shareholders.

• Enhancements to Govt Compensation Packages: Since 2019, the Board has engaged in a concerted multi-year effort to solicit and reply to shareholder suggestions associated to the Firm’s govt compensation packages. Shareholder suggestions acquired by these engagement efforts led to the implementation of significant adjustments to Alkermes’ govt compensation packages and different governance adjustments.

• Restricted the Variety of Public Firm Boards on Which Administrators Might Serve: In Might 2022, the Board revised its “overboarding” coverage to additional restrict the variety of public firm boards on which the Firm’s administrators might serve, together with that the Firm’s CEO or different worker administrators might serve on a most of 1 exterior public firm board and the Firm’s non-employee administrators might serve on a most of three different public firm boards (along with the Alkermes Board).

ALKERMES EXPANDED ITS PORTFOLIO OF PRODUCTS AND ADVANCED ITS PIPELINE PROGRAMS 

Alkermes has been constantly executing on quite a few initiatives to drive shareholder worth. The Firm has efficiently expanded its business portfolio by securing regulatory approvals of two new Alkermes-developed merchandise, grown its revenues from proprietary merchandise, and superior and expanded its pipeline beneath a brand new, disciplined growth strategy. These achievements embrace:

Two New Product Approvals

• In 2021, secured U.S. Meals and Drug Administration (“FDA”) approval and launched LYBALVI, an oral drugs for the therapy of schizophrenia and bipolar I dysfunction.
• In 2019, secured FDA approval of VUMERITY® for the therapy of relapsing types of a number of sclerosis, and supported Biogen’s business launch of this product.

Progress of Proprietary Industrial Product Portfolio

• Grew proprietary business product web gross sales from $524 Million in 2019 to $777 million in 2022, representing progress of 48%.
• Generated sturdy preliminary uptake of LYBALVI that exceeded analyst expectations within the first yr of launch; by the primary quarter of 2023, greater than 9,300 healthcare suppliers had written a prescription for LYBALVI and greater than 115,000 prescriptions for LYBALVI had been disbursed.
• Re-established VIVITROL® progress within the dependancy therapy system following COVID-19-related disruptions, and redefined VIVITROL’s business technique within the alcohol dependence indication.
• Drove progress of ARISTADA®, together with, most just lately, 10% year-over-year progress within the first quarter of 2023.

Development of Neuroscience and Oncology Improvement Pipeline

• Initiated section 1 first-in-human examine for ALKS 2680, Alkermes’ orexin 2 receptor agonist, enrolling preliminary cohorts and dosing topics effectively forward of anticipated timelines, with preliminary medical proof-of-concept knowledge anticipated earlier than year-end 2023.
• Superior nemvaleukin alfa (“nemvaleukin”) into potential registrational trials in two tumor varieties and secured each FDA Quick Observe designation for nemvaleukin in mucosal melanoma and together with pembrolizumab in platinum-resistant ovarian most cancers, and FDA Orphan Drug designation for nemvaleukin in mucosal melanoma.

Energetic Administration of Royalty and Manufacturing Enterprise

• Secured a number of profitable interim awards within the Firm’s binding arbitration proceedings towards Janssen Pharmaceutica N.V. (“Janssen”), a subsidiary of Johnson & Johnson, associated to its partial termination of two license agreements with the Firm and Janssen’s choice to stop paying royalties on sure merchandise within the U.S. Pursuant to the interim awards, the arbitration panel discovered that, however its termination of the license agreements, Janssen should proceed to pay the Firm royalties on the relevant merchandise within the U.S. and that the Firm is entitled to such royalties for 15 years from first business sale of every such product. Sarissa beforehand cited the Janssen dispute as a cause for deciding to submit a nomination discover in 2022. Alkermes expects to obtain a last award sooner or later and plans to replace its 2023 monetary expectations accordingly.

THE ALKERMES BOARD AND MANAGEMENT TEAM HAVE BEEN DRIVING CHANGE FOCUSED ON OPERATIONAL EFFICIENCY, DISCIPLINED CAPITAL ALLOCATION, AND PROFITABILITY

The Board and Alkermes’ administration group have been keenly centered on the next targets to greatest place Alkermes for long-term progress and worth creation:

• Execute on the Firm’s December 2020 Worth Enhancement Plan.
• Drive operational effectivity and calibrate Alkermes’ price construction to appropriately help the Firm’s strategic priorities and progress alternatives.
• Work towards the deliberate separation of the oncology enterprise.

Alkermes has taken substantial actions to optimize its price construction over the previous 4 years in response to the evolving wants of the Firm and shareholder suggestions, and in help of its dedication to driving shareholder worth creation. 

Worth Enhancement Plan. The December 2020 Worth Enhancement Plan is comprised of quite a few initiatives, together with Board refreshment, analysis of strategic alternatives and institution of long-term profitability targets. This Plan was knowledgeable by direct engagement with, and suggestions from, a lot of Alkermes’ largest institutional shareholders all through 2019 and 2020. Announcement of the Plan adopted constructive dialogue and entry right into a cooperation settlement with Elliott.

Price Construction Optimization. In 2019, previous to its interactions with Sarissa or Elliott, Alkermes carried out a restructuring, which included headcount reductions and different cost-saving measures. As well as, in 2020, the Firm adopted a revised analysis and growth (“R&D”) capital allocation technique centered on prioritizing R&D packages that it believes supply the very best potential return on funding. That disciplined technique resulted within the discontinuation of a number of early-stage growth packages based mostly on data-driven choice making towards pre-defined success standards and R&D stage-gates. In 2020, Alkermes carried out a reorganization of the Firm’s business group in preparation for the launch of LYBALVI, consolidating a number of useful areas to drive working leverage and allocating assets to successfully drive progress. 

Separation of the Oncology Enterprise. In November 2022, following a sturdy analysis course of, Alkermes introduced the deliberate separation of its oncology enterprise from its neuroscience enterprise. The Firm submitted a confidential draft Type 10 for this transaction in April 2023 and expects the separation to be accomplished within the second half of 2023. The Board unanimously agreed that the distinctive wants of every enterprise can be greatest served by simplified useful resource and capital allocation choice making, tailor-made working constructions, and distinct management groups, every with a clearly outlined strategic focus. Following the deliberate separation of the oncology enterprise, Alkermes can be a pure-play, commercial-stage neuroscience firm, retaining its give attention to vital unmet wants inside neuroscience and on driving progress of its proprietary business merchandise: LYBALVI, ARISTADA/ARISTADA INITIO®, and VIVITROL. The separated oncology enterprise, just lately named Mural Oncology, can be a pure-play oncology firm, centered on the invention and growth of most cancers therapies, together with the continued growth of nemvaleukin and the Firm’s portfolio of novel, preclinical engineered cytokines, comprised of tumor-targeted cut up interleukin-12 (IL-12) and interleukin-18 (IL-18).

Accelerated Profitability Targets*. In February 2023, the Firm accelerated its long-term profitability targets to replicate the anticipated monetary good thing about the deliberate separation of the oncology enterprise within the second half of 2023, and introduced its dedication to reaching the next:

• FY 2024 non-GAAP web earnings equal to 25% of the Firm’s whole revenues and EBITDA3 margin of 20% of whole revenues
• FY 2025 non-GAAP web earnings equal to 30% of the Firm’s whole revenues and EBITDA margin of 25% of whole revenues

The Firm didn’t present reconciliations of, or comparable GAAP measures for, the above non-GAAP profitability targets, as they aren’t determinable with out unreasonable efforts.

ALKERMES’ PROGRESS, BUSINESS MOMENTUM, AND POTENTIAL HAS BEEN RECOGNIZED BY SELL-SIDE ANALYSTS

Current commentary from sell-side analysts consists of:

“ALKS clearly has the flexibleness to not solely effectuate the spin-out of a funded oncology enterprise but in addition execute on the addition of belongings that may bolster the neuropsychiatry pipeline. We imagine that ALKS is well-positioned for significant additional worth creation.”
– David Amsellem, Piper Sandler (April 26, 2023)

“Concerning the arbitration with J&J, we’re not stunned that Alkermes received this case. We have now by no means understood why J&J believed that it did not owe Alkermes the suitable and normal CM/royalties and that it may attempt to get out of this settlement. . . Concerning the choice to hive off the oncology enterprise, we stay very supportive that this can be a good transfer.”
– Marc Goodman, SVB Securities (April 26, 2023)

“We stay bullish on ALKS. We proceed to imagine the deliberate separation would unlock worth for the oncology enterprise and the standalone neuroscience firm, reworking it right into a extra enticing entity given the potential blockbuster alternative from LYBALVI and ALKS 2680 (orexin 2 agonist) and the leaner working price construction.”
– Uy Ear, Mizuho (April 26, 2023)

“Outperformance has been delivered, in our view, on a lovely mixture of business supply (stable 4Q22 business outcomes and FY2023 steerage), the declaration of a extra centered technique (with the deliberate separation of the oncology and neuroscience companies), and the emergence of a pipeline asset, ALKS 2680.”
– Chris Shibutani, MD, Goldman Sachs (April 18, 2023)

“ALKS put up considered one of its higher Q’s in yrs. The ’23 information was stable–LYBALVI information was ~5% larger vs cons. & implies inflection in ’23 probably on the again of DTC efforts…. This stays the most effective thought in our protection given base enterprise execution + blue sky upside w/OX2.”
– Akash Tewari, Jefferies (February 16, 2023)

“We agree with ALKS’s choice to focus the enterprise on neuroscience…we see the corporate on the cusp of a major transition with introduced plans to separate the oncology effort right into a separate enterprise permitting extra direct give attention to reaching improved profitability for the neuroscience enterprise.”
– Jessica Fye, JP Morgan (February 14, 2023)

PLEASE VOTE USING THE COMPANY’S WHITE PROXY CARD TODAY

The Board has nominated seven director nominees for re-election to the Board on the Annual Assembly: Emily Peterson Alva, Shane M. Cooke, Richard B. Gaynor, M.D., Cato T. Laurencin, M.D., Ph.D., Brian P. McKeon, Richard F. Pops and Christopher I. Wright, M.D., Ph.D. The Board recommends that shareholders vote ‘FOR’ all seven of the Board’s director nominees utilizing the WHITE proxy card. The Firm’s proxy assertion and different vital info and assets associated to the Annual Assembly might be discovered at www.AlkermesValue.com.

There are three simple methods to vote:

BY INTERNET

BY TELEPHONE

BY MAIL

Go to the web site proven in your
WHITE proxy card

Dial the toll-free quantity proven on
your WHITE proxy card
(obtainable 24/7)

Mark, date, signal and return the
WHITE proxy card within the postage-paid
envelope supplied

You probably have any questions on tips on how to vote your shares, or want help in voting, please contact the agency helping Alkermes with the solicitation of proxies for the Annual Assembly:

Innisfree M&A Integrated
Toll-Free at (877) 750-8334 (toll-free for these calling from the U.S. and Canada) or
+1 (412) 232-3651 (for these calling from exterior the U.S. and Canada)

To be taught extra about Alkermes’ Board nominees, enterprise technique, and robust current efficiency, please go to www.AlkermesValue.com.

Alkermes seems ahead to speaking with you additional because the Annual Assembly approaches, and as at all times, appreciates your continued help.

Sincerely,

The Alkermes Board of Administrators

About Alkermes plc
Alkermes plc is a fully-integrated, international biopharmaceutical firm growing modern medicines within the fields of neuroscience and oncology. The corporate has a portfolio of proprietary business merchandise centered on alcohol dependence, opioid dependence, schizophrenia and bipolar I dysfunction, and a pipeline of product candidates in growth for most cancers and neurological issues. Headquartered in Dublin, Eire, Alkermes has a analysis and growth middle in Waltham, Massachusetts; a analysis and manufacturing facility in Athlone, Eire; and a producing facility in Wilmington, Ohio. For extra info, please go to Alkermes’ web site at www.alkermes.com.

Ahead-Wanting Statements
Sure statements set forth on this press launch represent “forward-looking statements” throughout the that means of the Personal Securities Litigation Reform Act of 1995, as amended, together with, however not restricted to, statements in regards to the Firm’s expectations regarding its future monetary and working efficiency, enterprise plans or prospects, together with its skill to execute on its technique and create and ship progress and shareholder worth and its skill to attain long-term profitability and its profitability targets; the Firm’s engagement with Sarissa; expectations with respect to the ultimate award within the Firm’s arbitration proceedings with Janssen and the Firm’s plans to replace its 2023 monetary expectations; expectations concerning the timing, construction, anticipated advantages and different impacts of the deliberate separation of the Firm’s oncology enterprise; timelines, plans and expectations for growth actions referring to ALKS 2680; and the therapeutic and business potential of the Firm’s merchandise. The Firm cautions that forward-looking statements are inherently unsure. The forward-looking statements are neither guarantees nor ensures and they’re essentially topic to a excessive diploma of uncertainty and danger. Precise efficiency and outcomes might differ materially from these expressed or implied within the forward-looking statements as a result of varied dangers and uncertainties, together with that the Firm might not in the end separate its oncology enterprise throughout 2023 or in any respect; unanticipated developments, prices or difficulties which will delay or in any other case negatively have an effect on a possible separation of the Firm’s neuroscience and oncology companies; the Firm might not be capable of obtain long-term profitability or its profitability targets in a well timed method or in any respect; the phrases of the ultimate award to be issued within the Firm’s arbitration proceedings with Janssen might differ from the phrases of the interim awards issued in such arbitration proceedings and could also be challenged by Janssen; medical growth actions is probably not accomplished on time or in any respect; the outcomes of the Firm’s growth actions is probably not constructive, or predictive of ultimate outcomes from such actions, outcomes of future growth actions or real-world outcomes; the FDA or regulatory authorities exterior the U.S. might not agree with the Firm’s regulatory approval methods or elements of the Firm’s advertising purposes; the FDA or regulatory authorities exterior the U.S. might make hostile selections concerning the Firm’s merchandise; the Firm and its licensees might not be capable of proceed to efficiently commercialize their merchandise or help income progress from such merchandise; the Firm’s merchandise might show tough to fabricate, be precluded from commercialization by the proprietary rights of third events, or have unintended negative effects, hostile reactions or incidents of misuse; and people dangers and uncertainties described beneath the heading “Danger Components” within the Firm’s Annual Report on Type 10-Ok for the yr ended Dec. 31, 2022 and in subsequent filings made by the Firm with the SEC, which can be found on the SEC’s web site at www.sec.gov. Present and potential traders are cautioned to not place undue reliance on these forward-looking statements, which communicate solely as of the date hereof. Besides as required by legislation, the Firm disclaims any intention or accountability for updating or revising any forward-looking statements contained on this press launch.

Vital Extra Info and The place to Discover It
The Firm has filed its definitive proxy assertion, accompanying WHITE proxy card and different related paperwork with the SEC in reference to the solicitation of proxies for the Annual Assembly. BEFORE MAKING ANY VOTING DECISION, SHAREHOLDERS OF THE COMPANY ARE URGED TO READ ALL RELEVANT DOCUMENTS FILED WITH OR FURNISHED TO THE SEC, INCLUDING THE COMPANY’S DEFINITIVE PROXY STATEMENT AND ANY AMENDMENTS AND SUPPLEMENTS THERETO, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. Traders and shareholders will be capable of get hold of a replica of the definitive proxy assertion and different paperwork filed by the Firm with the SEC freed from cost from the SEC’s web site at www.sec.gov. As well as, copies can be obtainable at no cost by visiting the “Traders” part of the Firm’s web site at www.alkermes.com, as quickly as moderately practicable after such supplies are filed with, or furnished to, the SEC.

Sure Info Concerning Members within the Solicitation
The Firm, its administrators and sure of its govt officers are members within the solicitation of proxies from shareholders in respect of the Annual Assembly. Info concerning the names of such members and their respective pursuits within the Firm, by safety holdings or in any other case, is ready forth within the Firm’s definitive proxy assertion for the Annual Assembly, which might be obtained freed from cost from the sources indicated above.

Non-GAAP Monetary Measures
This press launch consists of details about sure monetary measures that aren’t ready in accordance with GAAP, together with non-GAAP web earnings margin (non-GAAP web earnings/whole income) and EBITDA margin (EBITDA/whole income). These non-GAAP measures usually are not based mostly on any standardized methodology prescribed by GAAP and usually are not essentially similar to comparable measures offered by different firms. Non-GAAP web earnings adjusts for sure one-time and non-cash costs by excluding from GAAP outcomes: share-based compensation expense; amortization; depreciation; non-cash web curiosity expense; change within the honest worth of contingent consideration; sure different one-time or non-cash gadgets; and the earnings tax impact of those reconciling gadgets.

The Firm’s administration and Board make the most of these non-GAAP monetary measures to judge the Firm’s efficiency. The Firm offers these non-GAAP monetary measures of the Firm’s efficiency to traders as a result of administration believes that these non-GAAP monetary measures, when considered with the Firm’s outcomes beneath GAAP and the accompanying reconciliations, are helpful in figuring out underlying developments in ongoing operations. Nonetheless, non-GAAP web earnings margin and EBITDA margin usually are not measures of economic efficiency beneath GAAP and, accordingly, shouldn’t be thought of as alternate options to GAAP measures as indicators of working efficiency. Additional, non-GAAP web earnings margin and EBITDA margin shouldn’t be thought of measures of the Firm’s liquidity.

*The Firm has not supplied full monetary expectations for time durations after the yr ending Dec. 31, 2023 and due to this fact shouldn’t be offering reconciliations of, or comparable GAAP measures for, non-GAAP web earnings margins or EBITDA margins, for time durations after the yr ending Dec. 31, 2023. Reconciliations of such forward-looking non-GAAP profitability measures to comparable GAAP measures usually are not determinable with out unreasonable efforts as a result of inherent issue in forecasting and quantifying sure future monetary quantities vital for such reconciliations, which quantities may have a major impression on the Firm’s future monetary outcomes, together with such non-GAAP profitability measures and the comparable GAAP monetary measures.

Contacts:
For Traders:  Sandy Coombs, +1 781 609 6377
For Media:  Katie Joyce, +1 781 249 8927

Or

FGS World
Chris Kittredge / Zachary Tramonti
[email protected]

1 Friends embrace: Acadia Prescription drugs Inc., Alnylam Prescription drugs, Inc., Blueprint Medicines Company, Emergent BioSolutions Inc., Exelixis, Inc., Horizon Therapeutics plc, Incyte Company, Ionis Prescription drugs, Inc., Ironwood Prescription drugs, Inc., Jazz Prescription drugs plc, Neurocrine Biosciences, Inc., PTC Therapeutics, Inc., Sage Therapeutics, Inc., Sarepta Therapeutics, Inc., Ultragenyx Pharmaceutical Inc., United Therapeutics Company.

2 Share costs from 12/9/2020, the final buying and selling day earlier than Alkermes introduced its Worth Enhancement Plan, by 2/3/2023, the final buying and selling day previous to Sarissa’s Schedule 13D/A disclosing its discover of director nominations

3 Calculated as earnings earlier than curiosity, taxation, depreciation, amortization and one-time gadgets, consists of share-based compensation bills.

SOURCE Alkermes plc